Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Sarepta Therapeutics, Inc.”

102 pharma patents match "Sarepta Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 102
Index total 30,257
Page 1 / 5

Quick answer

This filtered view shows 102 pharmaceutical patents matching "Sarepta Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

102 results for “Sarepta Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12377150

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12370261

    Chimeric peptides for antisense delivery

    Sarepta Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  3. US 12286630

    Treatment methods for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  4. US 12239715

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  5. US 12168059

    Trimeric peptides for antisense delivery

    Sarepta Therapeutics, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  6. US 12139709

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Sarepta Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  7. US 12138312

    Cell-penetrating peptides for antisense delivery

    Sarepta Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  8. US 12121532

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Sarepta Therapeutics, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  9. US 12104163

    Adeno-associated virus vectors for treatment of Rett syndrome

    Sarepta Therapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  10. US 11932851

    Exon skipping compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  11. US 11925675

    Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  12. US 11911403

    Antisense-induced exon exclusion in type VII collagen

    Sarepta Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  13. US 11732259

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  14. US 11674139

    Oligonucleotides for treating expanded repeat diseases

    Sarepta Therapeutics, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  15. US 11672871

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  16. US 11642364

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  17. US 11555189

    Antisense oligomer compounds

    Sarepta Therapeutics, Inc. · Granted Jan 17, 2023 · Expires Jan 12, 2043

    granted
  18. US 11491238

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted
  19. US 11395855

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  20. US 11382981

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  21. US 11338041

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  22. US 11236329

    Compound and method for treating myotonic dystrophy

    Sarepta Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  23. US 11236338

    Antisense-induced exon2 inclusion in acid alpha-glucosidase

    Sarepta Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  24. US 11225662

    Peptide oligonucleotide conjugates

    Sarepta Therapeutics, Inc. · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted